Pharmacy White Coat Ceremony For Class of 2020
On Friday, Aug. 19, the University of Cincinnati James L. Winkle College of Pharmacy welcomed 93 new students to the Class of 2020 Doctor of Pharmacy program by presenting students with their white coats, a symbol of their entry into the health care profession.
The event was held in Kresge Auditorium in the CARE/Crawley building on the University of Cincinnatis Medical Campus and hosted speakers from the college, the Academic Health Center, alumni and professional organizations to include the Ohio Board of Pharmacy, the Ohio Pharmacists Association and the Ohio Society of Health Systems Pharmacists.
William Ball, MD, senior vice president for health affairs, Christian R. Holmes Professor and Dean of the College of Medicine, gave the universitys welcome remarks, noting the distinctions of this class as having an average 3.5 GPA, and a PCAT (Pharmacy College Admission Test) score of 70. More than half of the class, 53 percent, entered after earning their undergraduate degrees at UC, and 71 percent of the class hails from Ohio. Sixteen percent of the class is made up of minorities, and females (63) make up more than half of the class.
Students were called to the stage by Andrea Wall, the associate dean for student affairs, and "coated by Dean Neil MacKinnon, PhD. Each student received a congratulatory handshake from Dean Ball.
As the role of the pharmacists is ever expanding, Dean Ball noted that when the class graduates in 2020 they will be trained to provide services such as immunizations and medication management; services that pharmacists "ten years ago would never have dreamed of doing.
Funds for the coats are provided by pharmacy alums, and a card with each donors name is presented to the student.
Related Stories
Study: Additional radiation for liver cancer does not increase toxicity
March 10, 2026
New research led by University of Cincinnati Cancer Center researchers published in the American Journal of Clinical Oncology found external beam radiation therapy (EBRT) is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.
Phase 1 trial tests probiotic treatment for radiation side effects in the gut
March 9, 2026
The University of Cincinnati Cancer Center’s Bailey Nelson, MD, has been awarded a $50,000 pilot grant from the Cancer Center to open a Phase 1 trial testing if a probiotic supplement can reduce gastrointestinal symptoms for patients undergoing whole pelvis radiotherapy.
Is uACR the key to cardiovascular and kidney disease prevention?
March 8, 2026
As a precision biomarker, the urinary albumin-to-creatinine ratio (uACR) can guide physicians toward personalized, patient-centered prevention and treatment of both cardiovascular disease (CVD) and chronic kidney disease (CKD), according to new data published in the Journal of Internal Medicine.